No Data
BOCOM INTL: Assigns a "Leading" rating to the domestic Pharmaceutical Industry. Shanghai establishes a 10 billion yuan M&A Fund, which is beneficial for accelerating industry consolidation.
BOCOM INTL believes that the pharmaceutical Sector still has further room for recovery.
【Brokerage Focus】FIRST SHANGHAI gives AKESO (09926) a "Buy" rating, indicating that the R&D pipeline has initially shown world-class potential.
Jingu Financial News | FIRST SHANGHAI issued a Research Report indicating that AKESO (09926) saw its product revenue increase by 24% to 0.94 billion yuan in the first half of 2024, where the revenue from Cardunili rose by 16.5% to 0.71 billion yuan; Pembrolizumab generated 0.13 billion yuan, and Ivosidenib generated 0.1 billion yuan. Along with royalty income, the company recorded total revenue of 1.03 billion yuan, with a gross margin of 91.3%. Research and development expenses increased by 3% to 0.59 billion yuan, resulting in a net loss attributable to shareholders of 0.24 billion yuan. The company had net cash on hand of 2.4 billion yuan as of 2024. There were two placements in 2024 (in March and October) which raised 1.17 billion and 19.2 million respectively.
GF Securities Starts Akeso at Buy With HK$81.59 Price Target
Guosen's 2025 strategy for csi sws health care index: Innovation leads to industrial upgrade.
Current domestic medical demand continues to upgrade, the macro economy is expected to gradually warm up, and under geopolitical disturbances, the country is likely to increase support for self-controllable initiatives.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
No Data
MayFlower : It was predictable..
Midnite52 : yep